Results 111 to 120 of about 8,151 (283)

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

open access: yes, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran   +2 more
core   +1 more source

Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease

open access: yesJournal of health economics and outcomes research
Background: The mainstay first-line therapy for chronic graft-vs-host disease (cGVHD) is corticosteroids; however, for steroid-refractory patients, there is a distinct lack of cost-effective or efficacious treatment.
Adrian Peacock   +8 more
semanticscholar   +1 more source

Extracorporeal photopheresis vs standard therapies for steroid‐refractory chronic graft‐vs‐host disease: Pharmacoeconomic assessment of hospital resource use in Spain [PDF]

open access: hybrid, 2021
Blanca Boluda   +19 more
openalex   +1 more source

Low‐dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S‐MISR Study

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 12, Page 1534-1542, December 2025.
Summary Background Erythrodermic mycosis fungoides (eMF) and Sézary syndrome (SS) often show delayed and non‐durable clinical responses to systemic therapies. Patients and Methods A total of 35 patients with eMF or SS were treated with total skin electron beam therapy (TSEBT).
Khaled Elsayad   +14 more
wiley   +1 more source

Evaluating a New Photopheresis System: A Comparison with Two Established Systems on Cell Yield and Collection Efficiency

open access: yesDiagnostics
Background/Objectives: Extracorporeal photopheresis (ECP) is a well-established and efficacious cell therapy for a range of diseases. The objective of this retrospective study was to compare the new Amicus Blue inline system with the Therakos Cellex ...
Orkan Kartal   +5 more
doaj   +1 more source

Sign of Leser-Trélat and Cutaneous T-Cell Lymphoma: A Rare Association

open access: yesDermatopathology, 2018
Sign of Leser-Trélat is a rare paraneoplastic cutaneous manifestation, characterized by the sudden appearance and rapid increase in size and number of seborrheic keratoses, accompanied by pruritus.
Raphaël André   +5 more
doaj   +1 more source

BUSM Dean's report [PDF]

open access: yes, 1990
Reports from the Office of the Dean, Boston University School of ...
Office of the Dean, Boston University School of Medicine
core  

Recent insights into extracorporeal photopheresis for graft-versus-host disease

open access: yesExpert Review of Clinical Immunology
Introduction Extracorporeal Photopheresis (ECP) may be considered the unique large-scale cell therapy currently available. It is currently employed mainly as second-line treatment, especially in steroid-resistant or steroid-dependent Graft versus Host ...
C. Del Fante, C. Perotti
semanticscholar   +1 more source

A validation study of the in vitro performance of hypoxic red blood cells for transfusion across centers in Europe

open access: yesTransfusion, Volume 65, Issue 12, Page 2306-2315, December 2025.
Abstract Background Refrigerated storage of red cell concentrate (RCC) leads to metabolic, oxidative, and structural changes that impair functionality and viability. These changes can be attenuated by hypoxic storage. Objective This study assessed the quality of leucocytes‐reduced (LR), O2/CO2 reduced red blood cells (RBC) stored for 42 days after pre ...
Vanessa Agostini   +12 more
wiley   +1 more source

A survey of extracorporeal photopheresis treatment in pediatric patients in the United Kingdom

open access: yeseJHaem, 2020
Extracorporeal photopheresis (ECP) is a second‐line therapy in acute and chronic GVHD and solid organ transplant rejection. We report ECP use in 98 pediatric patients in seven UK centers from 2010 to 2017, the majority treated for aGVHD (73.5%).
Aisling M. Flinn   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy